HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine
about
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of ageEffectiveness of antiretroviral therapy in HIV-infected children under 2 years of ageHIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backboneDevelopment of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, MozambiqueConcordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialThe use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010.Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique.Clinical implications of HIV-1 minority variantsThe changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents.HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in UgandaA post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes.Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.High Rates of Baseline Drug Resistance and Virologic Failure Among ART Naïve HIV-Infected Children in Mali.Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.The pharmacological treatment of acute HIV infections in neonates.
P2860
Q24194589-7A92268A-E484-48CF-B8B7-0EDDEA38D119Q24202004-455D693F-A2EB-45AA-86DE-88E460C5053EQ28482189-3E268A71-0001-4197-BDB1-5143F58A7F56Q28546418-A59D42D1-2C30-4E96-8B39-5663C5259276Q34112568-A1FDA14D-C217-42A7-A0D3-CA5544E3A4D5Q35965344-B2AF477C-9089-4DB9-91B6-B61628977A1AQ35965440-7C22565D-BDE4-4247-AF49-261B2661423BQ36032235-313720E8-425E-4460-8C3A-D723BAD9DFE9Q36049082-4024DD3B-2FE2-4404-AF28-B6C0D36D9353Q36060517-7B5D3844-A355-4DCA-9A99-BAB2C68E2A01Q36186007-BFE57093-95E6-4FF8-8353-C47B4782FA0EQ36238419-7EF19141-82A6-4AF4-9DAD-6584B8B4F765Q36611206-EFD45E71-EDDA-421B-8BDA-513C38434947Q36811249-75958BDD-C497-4F9A-94A9-8C15749CFE65Q36941665-ED27F96E-3394-4144-A106-587ACA39023FQ37062207-C9BAAB83-68AA-4ACF-9029-873F4469CBEBQ37320315-EA10C750-F5A9-40D4-A5B4-73DFEC1DB6FBQ37322060-7342A665-57CA-4388-B0EB-26CA9B1FDDE6Q37410105-6E2C1947-F200-4390-85B4-A37AB013CB2BQ37581844-35EF436A-0630-4299-B656-F9BF05D9DE34Q38913062-8B6F75DA-1487-48F7-B8D0-AAF9F994B974Q38960646-8748D98D-C8B2-4F4A-A29F-5F949B3C2986Q40238381-0B90560A-0A5F-4F93-A3A2-82CBE7D44FB9Q40291462-ABB5D8BF-10A4-484C-942E-23765BBF2C17Q43480455-BF5A5F2C-E061-4725-A88E-ACE5F0E04361Q47591909-B2F56034-D09D-4C96-9A62-29035179A1A3
P2860
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@ast
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@en
type
label
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@ast
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@en
prefLabel
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@ast
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@en
P2093
P2860
P50
P1433
P1476
HIV-1 drug resistance at antir ...... osed to single-dose nevirapine
@en
P2093
Gayle Sherman
Gillian M Hunt
Tammy Meyers
P2860
P304
P356
10.1097/QAD.0B013E3283492180
P407
P577
2011-07-01T00:00:00Z